Ms. Chandra Ganjoo, Group Chief Executive Officer, Trivitron Healthcare, said, “Our dedicate R&D team has conducted an in-silico analysis, ensuring that Trivitron’s cutting-edge COVID-19 testing kits, including COVIDSure, COVIDSure PRO, and COVIDSure Direct RT-PCR Kits, possess the capability to effectively detect the heavily mutated JN.1 strain of the SARS-CoV-2 virus. Our testing kits are meticulously designed to target the conserved regions of SARS-CoV-2, including ORF1ab, Envelope E-gene, and Nucleocapsid N-gene, ensuring the reliable detection of the JN.1 mutation without compromise. Additionally, our Trivitron BIOCARD Pro COVID-19 Rapid Antigen Kit, based on immunochromatography, focuses on the conserved region of the N gene, providing a robust qualitative detection method even in the presence of the JN.1 strain.”

She further added, “At Trivitron Healthcare, we remain committed to advancing diagnostic capabilities to address the evolving landscape of COVID-19 and its variants. These advancements are pivotal in facilitating accurate and timely diagnosis, especially in the face of emerging variants like JN.1, now classified as a “variant of interest” by the World Health Organization.”